| Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers F Fondevila, C Méndez-Blanco, P Fernández-Palanca, ... Experimental & molecular medicine 51 (9), 1-15, 2019 | 78 | 2019 |
| Antitumor effects of quercetin in hepatocarcinoma in vitro and in vivo models: a systematic review P Fernández-Palanca, F Fondevila, C Méndez-Blanco, MJ Tuñón, ... Nutrients 11 (12), 2875, 2019 | 65 | 2019 |
| Melatonin modulates mitophagy, innate immunity and circadian clocks in a model of viral‐induced fulminant hepatic failure I Crespo, P Fernández‐Palanca, B San‐Miguel, M Álvarez, ... Journal of Cellular and Molecular Medicine 24 (13), 7625-7636, 2020 | 39 | 2020 |
| Melatonin as an antitumor agent against liver cancer: an updated systematic review P Fernández-Palanca, C Méndez-Blanco, F Fondevila, MJ Tuñón, ... Antioxidants 10 (1), 103, 2021 | 37 | 2021 |
| Stabilization of hypoxia-inducible factors and BNIP3 promoter methylation contribute to acquired sorafenib resistance in human hepatocarcinoma cells C Méndez-Blanco, F Fondevila, P Fernández-Palanca, A García-Palomo, ... Cancers 11 (12), 1984, 2019 | 31 | 2019 |
| Prognostic and clinicopathological significance of hypoxia-inducible factors 1α and 2α in hepatocellular carcinoma: A systematic review with meta-analysis C Méndez-Blanco, P Fernández-Palanca, F Fondevila, ... Therapeutic Advances in Medical Oncology 13, 1758835920987071, 2021 | 21 | 2021 |
| Association of FOXO3 expression with tumor pathogenesis, prognosis and clinicopathological features in hepatocellular carcinoma: a systematic review with meta-analysis F Fondevila, P Fernandez-Palanca, C Mendez-Blanco, T Payo-Serafin, ... Cancers 13 (21), 5349, 2021 | 15 | 2021 |
| Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation P Fernández-Palanca, T Payo-Serafín, B San-Miguel, C Méndez-Blanco, ... Acta pharmacologica Sinica 44 (5), 1066-1082, 2023 | 9 | 2023 |
| Beneficial effects of melatonin on liver fibrosis: A systematic review of current biological evidence B San‐Miguel, P Fernández‐Palanca, JL Mauriz, MJ Tuñón, ... Journal of Cellular Physiology 237 (7), 2740-2757, 2022 | 9 | 2022 |
| Neuropilin-1 as a potential biomarker of prognosis and invasive-related parameters in liver and colorectal cancer: A systematic review and meta-analysis of human studies P Fernández-Palanca, T Payo-Serafín, F Fondevila, C Méndez-Blanco, ... Cancers 14 (14), 3455, 2022 | 8 | 2022 |
| Autophagy-related chemoprotection against sorafenib in human hepatocarcinoma: Role of FOXO3 upregulation and modulation by regorafenib F Fondevila, C Méndez-Blanco, P Fernández-Palanca, T Payo-Serafín, ... International Journal of Molecular Sciences 22 (21), 11770, 2021 | 8 | 2021 |
| Spatial modeling reveals nuclear phosphorylation and subcellular shuttling of YAP upon drug-induced liver injury L Wehling, L Keegan, P Fernández-Palanca, R Hassan, A Ghallab, ... Elife 11, e78540, 2022 | 7 | 2022 |
| Impact of aberrant β-catenin pathway on cholangiocarcinoma heterogeneity E Lozano, P Sanchon-Sanchez, A Morente-Carrasco, ... Cells 12 (8), 1141, 2023 | 6 | 2023 |
| Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications P Fernández-Palanca, T Payo-Serafín, C Méndez-Blanco, B San-Miguel, ... Clinical and Molecular Hepatology 29 (2), 293, 2023 | 5 | 2023 |
| Therapeutic approaches in intermediate-stage hepatocellular carcinoma (HCC): a novel insight of adjuvant transarterial chemoembolization (TACE) P Fernández-Palanca, JL Mauriz Chinese Clinical Oncology 12 (2), 11-11, 2023 | 1 | 2023 |
| Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity. Cells. 2023; 12: 1141 E Lozano, P Sanchon-Sanchez, A Morente-Carrasco, ... | 1 | 2023 |
| 180P A systematic review with meta-analysis of risks and benefits of tyrosine kinase inhibitors in hepatocellular carcinoma treatment J Martínez-Geijo, T Payo-Serafín, C Méndez-Blanco, PF Palanca, ... Annals of Oncology 35, S81, 2024 | | 2024 |
| Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials T Payo‐Serafín, C Méndez‐Blanco, P Fernández‐Palanca, ... Clinical Pharmacology & Therapeutics, 2024 | | 2024 |
| Mendez-Blanco et al. Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells (vol … C Mendez-Blanco, F Fondevila, P Fernandez-Palanca, A Garcia-Palomo, ... Cancers 15 (23), 2023 | | 2023 |
| Correction: Méndez-Blanco et al. Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma … C Méndez-Blanco, F Fondevila, P Fernández-Palanca, A García-Palomo, ... Cancers 15 (23), 5668, 2023 | | 2023 |
